Human milk oligosaccharides (HMOs) are reshaping infant nutrition, offering gut health benefits and bridging the gap between breast milk and formula. With innovations like Novonesis’ MyOli 5 HMO Mix and dsm-firmenich’s seven HMO blends at commercial scale, Nutrition Insight learns how the companies are developing personalized versions of the compounds for advanced baby formulas.According to Innova Market Insights data, there is a 12% CAGR between October 2019 to September 2024 for baby and toddler food launches with HMO ingredients. Europe is in the lead (42%) followed by Asia (25%) and US/Canada (12%).
